Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Inclusion Criteria: PART A * Male or female adults aged 18 to 55 years inclusive at the time of signing the informed consent form (ICF), who are capable of, and willing to provide, informed consent * Healthy, as determined by Investigator assessment, including medical history, physical examination, and screening laboratory results * All dosing groups: hemoglobin level ≥ 8 grams per deciliter (g/dL) * All dosing groups: living within local jurisdiction of trial site(s) and available for the duration of the trial for all cohorts * Female participants of childbearing potential must be nonpregnant and agree to avoid becoming pregnant by using an acceptable contraception method PART B * Age Cohort 2: male or female children aged 2 years to \<5 years at the time their parent or Legally Authorized Representative (LAR) signs the ICF * Age Cohort 3: male or female children aged 12 months to \<24 months at the time their parent or LAR signs the ICF * Age Cohort 4: male or female infant children aged 3 months to \<12 months and weighing at least 5 kilograms (kg) at the time their parent or LAR signs the ICF * Healthy, as determined by Investigator assessment, including medical history, physical examination, and screening laboratory results * Hemoglobin level ≥ 8g/dL * Height and weight Z-scores ≥-2 * Living within local jurisdiction of trial site(s) and available for the duration of the trial Exclusion Criteria: PART A \& PART B * Within 48 hours prior to randomization, acute feb…